BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1394@pharmaconomics
DTSTAMP:20260707T010112Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:PHVS Phase 3 — deucrictibant XR (estimated date)
DESCRIPTION:Phase 3 trial results for deucrictibant XR in HAE attacks are due ~ Sep 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1830487/000119312526219372/phvs-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1394
URL:https://www.pharmaconomics.com/e/1394
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PHVS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR